Congenital heart diseases are the most common birth defects, occurring in more than 1% of newborns. The gene regulatory network of cardiac development has been revealed and some cases of congenital heart diseases have been shown to be associated with cardiac-specific gene mutations or related chromosomal abnormalities; however, almost all cases of congenital heart diseases are sporadic and the pathogenesis of heart malformations still remains unknown. Recently, studies of epigenetic regulation have been making progress in the field of cardiac development and the accumulated knowledge helps us understand more about cardiogenesis and congenital heart diseases. Interestingly, pluripotent stem cells such as embryonic stem (ES) cells and induced pluripotent stem (iPS) cells have attracted attention as tools to dissect epigenetic regulation during differentiation. Reprogramming and differentiation of ES cells and iPS cells can be induced by changes of gene expression patterns and epigenetic regulation, not by changing DNA sequences. We can also modify histone patterns and chromatin structures using chemical reagents. Hence, pluripotent stem cells enable us to dissect and modify epigenetic regulation during cardiogenesis in vitro. Moreover, in terms of iPS cells, they have become disease models because they can be generated from the somatic cells of patients. In this review, we summarize the recent findings of epigenetic regulation in cardiac development and congenital heart diseases. We also review the epigenetic modification during the reprogramming and cardiac differentiation of ES cells and iPS cells, and introduce our study showing that the disease-specific iPS cells of hypoplastic left heart syndrome, one of the severest congenital heart diseases with single ventricular circulation, exhibit unique epigenetic regulation during differentiation. Furthermore, we briefly focus on modifications of epigenetic regulation in cardiac development using chemical reagents, which suggest the possibility of treating congenital heart diseases using drugs. Lastly, we discuss the epigenetic memory of iPS cells, a specific feature that often complicates or prevents study of the differentiation of iPS cells.
Introduction
Patients with congenital heart defects often need surgical treatment. Serious heart anomalies lead to high mortality and require sequential operations or heart transplantation. Recently, cardiovascular development has been well studied and numerous genes related to cardiogenesis have been confirmed [1] . Some gene mutations or chromosomal abnormalities were also found in patients with congenital heart diseases; however, almost all cases of congenital heart diseases are sporadic and the genetic background remains unknown. The lack of animal models for congenital heart diseases hampers the study of the pathogenesis. Recent studies have revealed the epigenetic regulation during cardiovascular development, and have also shown that impaired epigenetic modification during cardiogenesis causes congenital heart diseases [2, 3] . To understand cardiac development and the pathogenesis of congenital heart diseases, it might be necessary to understand epigenetic regulation. To investigate epigenetic modification during cardiac development, pluripotent stem cells such as embryonic stem (ES) cells and induced pluripotent stem (iPS) cells might be powerful tools because we can recapitulate cardiogenesis in the process of differentiation from pluripotent stem cells into cardiomyocytes in vitro. In terms of iPS cells, we can reset the disease phenotypes in the process of reprogramming when we generate these cells. In the processes of reprogramming and differentiation, genetic information remains unchanged, while the epigenetic regulation and expression pattern of genes change dynamically. Therefore, we can investigate the epigenetic changes during cardiogenesis in vitro by using pluripotent stem cells. This review focuses on the recent findings of epigenetic modification during cardiac development and congenital heart diseases, as well as investigation of epigenetic regulation using stem cell technologies. As an example to study the epigenetic regulation of congenital heart diseases by using pluripotent stem cells, we introduce our study of iPS cells from patients with hypoplastic left heart syndrome (HLHS), one of the severest congenital heart diseases with single ventricle circulation. Furthermore, we mention the possibilities of new therapy for cardiac malformations by using chemical reagents that modify epigenetic regulation, and discuss the recently emerged problem in studies on the differentiation of iPS cells: epigenetic memory.
Epigenetic regulation of cardiovascular development and congenital heart diseases
Epigenetic regulation mainly involves DNA methylation, ATP-dependent chromatin remodeling, and covalent histone modification. Recent studies have revealed that the regulation of ATP-dependent chromatin remodeling and covalent histone modification is related to cardiogenesis and the formation of congenital heart defects [2, 3] (Table 1) . The ATP-dependent chromatin-remodeling complexes consist of switching defective/sucrose nonfermenting (SWI/SNF), imitation switch (ISWI), chromodomain, helicase, DNA binding (CHD), and inositol requiring 80 (INO80) complexes. Other chromatin-modifying enzymes that catalyze the covalent modification of histones include histone deacetylases (HDACs), histone acetyltransferases (HATs), and histone methyltransferases (HMTs). These chromatin remodelers and histone modifiers coordinate to regulate cardiac development, and impaired regulation could cause the failure of cardiogenesis, leading to congenital heart diseases. In this section, we summarize the epigenetic regulation related to cardiogenesis and congenital heart diseases.
Regulation of vascular formation
Recent studies have demonstrated the epigenetic regulation during vascular development. Brg1, encoding the ATPase subunit of the BAF complex, is indispensable for yolk sac vascular development [4] . The deletion of Brg1 in smooth muscle cells of mice leads to persistence of patent ductus arteriosus (PDA) [5] . In addition, Baf180, a subunit of the BAF complex, is essential for coronary vessel formation [6] . Hdac7 as a class II HDAC is also related to vascular development, and Hdac7-disrupted embryo cannot maintain vascular integrity [7] . In vitro, HDAC7 silencing in endothelial cells was also shown to be associated with altered morphology, migration, and capillary structures [8] .
Regulation of heart formation
Numerous chromatin remodelers and histone modifiers have important roles in regulating heart formation. Brg1 in the endocardium regulates the establishment of cardiac jelly necessary for myocardial trabeculation via repressing Adamts1 [9] . The deletion of Brg1 in the myocardium causes ventricular septum defect (VSD) [10] . Deletion of Brg1 in the secondary heart field also causes hypoplastic outflow tract and right ventricle [10] . Knockdown of Baf60c, a component of BAF complexes, results in impaired secondary heart field formation [11] . Germline deletion of Baf180 in the mouse embryo is associated with hypoplastic ventricle and VSD [12] , as well as coronary vessel formation [6] . Deletion of both Hdac1 and Hdac2 in the myocardium is associated with dilated cardiomyopathy and arrhythmia [13] . In addition, doubly null mice of Hdac5 and Hdac9 show VSD [14] . The phenotypes of Sirt1 in class III HDAC deletion in mice show atrial septal defect (ASD), VSD, and heart valve defect [15] . Furthermore, point mutation of p300, a member of the HATs, leads to heart defects such as ASD and VSD [16] . The germline deletion of jumonji, a member of the jumonji family of histone demethylases, results in double outlet right ventricle (DORV) and hypertrabeculation [17] . Germline deletion of Smyd1, which encodes HMTs, causes ventricular hypoplasia [18] . Wolf-Hirschhorn syndrome candidate 1 (Whsc1) knockout mice exhibit ASD and VSD [19] . Finally, in patients with Kabuki syndrome, a mutation of mixed [20] .
Interaction between chromatin-remodeling/histonemodifying factors and transcription factors
These chromatin-remodeling and histone-modifying factors also interact with transcription factors that are related to cardiac development. For example, Brg1 regulates the expression of SRF/MRTFA-dependent genes involved in smooth muscle contraction [21] . Brg1 also interacts with cardiac transcription factors such as Nkx2.5, Tbx5, and Tbx20 in a dose-dependent manner [22] . In addition, combinatorial induction of Tbx5, Gata4, and Baf60c is necessary for reprogramming of beating cardiomyocytes [23] . Hdac2 interacts with Hop to inhibit the transcriptional activities of Gata4 [24] . p300 is also a co-activator of Gata4 via acetylating Gata4, leading to the promotion of DNA binding and transcriptional activities [25] . Another example involves Jarid2/Jumonji, which suppresses Notch1 expression in the endocardium [26] . In addition, Rae28, a polycomb repressive complex 1 (PRC1) member, is necessary for Nkx2.5 transcriptional activity [27] . Finally, Whsc1 associates with Nkx2.5 to regulate heart development [19] . As seen in this section, chromatin-remodeling and histone-modifying factors have multiple functions in the regulation of cardiogenesis.
Investigation of epigenetic modification using stem cell technologies
As shown in the previous section, numerous chromatin remodelers and histone modifiers regulate cardiac development and the failure of this regulation might cause congenital heart diseases. In order to investigate epigenetic modification during cardiac development in vitro, pluripotent stem cells such as ES cells and iPS cells might be useful. We can reset the disease phenotype in the process of reprogramming, and recapitulate cardiogenesis during differentiation in vitro without changing genetic information. Through investigation of the epigenetic regulation in pluripotent stem cells, we can research molecular mechanisms during reprogramming and cardiac differentiation ( Figure 1 ). In the following section, we summarize the epigenetic regulation in the process of reprogramming and cardiac development.
Epigenetic modification during reprogramming into iPS cells
In the process of generating iPS cells, the vectors encoding Yamanaka 4 factors such as Oct4, Klf4, Sox2, and Myc (called 'OKSM') are originally induced into somatic cells [28] . During cellular reprogramming, OKSM change the gene expression pattern and the epigenetic state of somatic cells into those of pluripotent stem cells without changing the DNA sequences. OKSM mainly achieve two functions epigenetically during reprogramming: releasing the program for somatic cells and initiation/maintenance of the state of pluripotent stem cells [29] . To perform these epigenetic modifications, OKSM bind to their target components [30] [31] [32] , interact with histone-modifying enzymes [33] [34] [35] , regulate the 3D structures of chromatins [36] , and trigger DNA methylation.
Chromatin dynamics during cardiomyocyte differentiation
We accumulated knowledge about the combinatorial expression of transcriptional factors during cardiac development; however, the epigenetic modifications in pluripotent stem cells during cardiac lineage induction are still poorly understood. However, recent studies have started to unveil the mechanisms involved [37, 38] . Paige et al. performed directed differentiation of human ES cells into cardiomyocytes and investigated the chromatin modification in this process of differentiation [37] . They investigated the modification of trimethylated histone H3-lysine 4 (H3K4me3), trimethylated histone H3-lysine 27 (H3K27me3), and trimethylated histone H3-lysine 36 (H3K36me3) along the time course of directed differentiation, including pluripotent stem cells (day-0), mesodermal progenitors (day-2), specified tripotential cardiovascular progenitors (day-5), committed cardiovascular cells (day-9), and definitive cardiovascular cells (day-14), by chromatin immunoprecipitation (ChIP)-sequencing. In terms of the results, most of the transcription factors that regulate cardiac development demonstrated increased H3K27me3 and decreased H3K4me3, H3K36me3, and RNA expression (indicating inactive promoters) at day-0, although H3K27me3 was gradually suppressed and H3K4me3, H3K36me3, and RNA expression increased (indicating active promoters) in the process of differentiation. H3K4me3, H3K36me3, and RNA expression for genes encoding cardiomyocyte structural proteins also increased along the time course of differentiation; however, H3K27me3 remained at undetectable levels throughout [39, 40] . Wamstad et al. differentiated mouse ES cells into cardiomyocytes and determined chromatin regulation at the phases of ES cells, mesoderm, cardiac precursors, and cardiomyocytes [38] . They showed that the functionally related genes expressed specific chromatin patterns, although the gene expression patterns were similar. For example, among the genes expressed at the cardiomyocyte stage, metabolism-related genes showed increased H3K4me3 and no H3K27me3, the signaling-related genes demonstrated increases of both H3K4me3 and H3K27me3, and in terms of the genes for muscle contraction, there was increased expression of H3K4me3 but no increase of H3K27me3. They also identified that monomethylated histone H3-lysine 4 (H3K4me1), related to the opening of chromatin at distal enhancers preceding activation [41, 42] , was deposited at transcriptional start sites preceding the increase of H3K4me3 and transcriptional activation in cardiac regulatory genes [38] .
In addition, Chow et al. differentiated human ES cells by a directed differentiation protocol and purified ventricular cardiomyocytes [43] . They reported that there were an increase of H3K4me3 and a decrease of H3K27me3 on the promoters of pluripotent genes such as OCT4, SOX2, and NANOG in human ES cells. In contrast, there were a decrease of H3K4me3 and an increase of H3K27me3 on the promoters of human ES cell-derived ventricular cardiomyocytes. Human ES cell-derived ventricular cardiomyocytes demonstrated enrichment of H3K4me3 and suppression of H3K27me3 on the promoters of ventricular myosin light chain (MYL2), atrial myosin light chain (MYL7), cardiac troponin T (TNNT2), and natriuretic peptide A (NPPA) compared with human ES cells. Upregulated H3K4me3 levels were also seen on the promoters of Ca 2+ -handling proteins, sodium and Investigation of epigenetic modification in hypoplastic left heart syndrome by using patient-specific iPS cells
As shown in the previous section, we have started to understand the epigenetic regulation of pluripotent stem cells during cardiomyocyte differentiation. Investigations of epigenetic regulation in patient-specific iPS cells during cardiac development might enable us to dissect the pathogenesis of congenital heart diseases. By using patient-specific iPS cells, we attempted to determine the epigenetic regulation during the cardiogenesis of HLHS, which is one of the severest congenital heart diseases with single ventricular circulation [44] . Some cases of HLHS are related to the mutation of cardiac-specific genes or associated chromosomal abnormalities; however, most of the cases are sporadic and the genetic basis has remained unknown. We generated five clones of iPS cells from the cardiac progenitor cells (CPCs) of patients with HLHS and investigated histone modifications in the process of cardiomyocyte differentiation. We performed ChIP assay on NKX2-5 promoter lesion of undifferentiated iPS cells, CPCs, and cardiomyocytes differentiated from HLHS-derived iPS cells and compared the results with those from biventricular heart (BV)-derived cells. In the undifferentiated iPS cells and CPCs, there were no significant differences in dimethylated histone H3-lysine 4 (H3K4me2), H3K27me3, and acetylated histone H3 (acH3) on NKX2-5 promoter lesion between HLHS-derived cells and BV-derived cells. However, the differentiated iPS cells demonstrated significant decreases of H3K4me2 and acH3 and a significant increase of H3K27me3 on NKX2-5 promoter lesion of HLHS-derived iPS cells compared with BV-derived iPS cells. These results indicated that HLHS-iPS-derived cardiomyocytes had suppressed promoter activity of NKX2-5 compared with BV-iPS-derived cardiomyocytes. Correlated with these results, the gene expression of NKX2-5 was significantly downregulated in HLHS-iPS-derived cardiomyocytes compared with that of BV-iPS-derived ones, as determined by quantitative RT-PCR. Furthermore, reporter assay demonstrated that the induction of NKX2-5 into HLHS-derived CPCs and iPS cells contributed to the restoration of cardiac-specific promoter activities such as serum response elements, TNNT2, and NPPA to levels equivalent to those of BV-derived cells. These findings suggested that NKX2-5 might be an essential transcription factor for the pathogenesis of HLHS. Interestingly, suppression of H3K4me2 and acH3 and an increase of H3K27 on NKX2-5 promoter lesion were found only in the differentiated HLHS-iPS-derived cardiomyocytes, not in the undifferentiated iPS cells or CPCs, and the significant suppression of NKX2-5 gene expression was only seen in the HLHS-iPS-derived cardiomyocytes, not in HLHS-derived iPS cells. Considering that NKX2-5 is a cardiac-specific transcription factor [45] , these findings suggest that histone modification of NKX2-5 is specific at the stage of differentiation and impaired transient epigenetic activation of NKX2-5 might cause the suppressed NKX2-5 expression of HLHS-iPS-derived cardiomyocytes.
The possibility of improving epigenetic regulation during cardiogenesis
Some experimental data have shown that impaired epigenetic regulation affects cardiac development. In fact, some reported cases of congenital heart diseases were caused by the mutation of genes controlling epigenetic regulation. In addition to the gene regulatory network during cardiac development, we should take the epigenetic regulation into consideration when we think about the pathogenesis of congenital heart diseases. Furthermore, by utilizing the knowledge of epigenetic regulation during cardiac development, we could have a new approach to improve cardiac development and treat congenital heart diseases. When it comes to the therapies of congenital heart diseases, the major strategy is operation; however, we might treat such diseases during and after cardiac development if we can change the impaired epigenetic regulation. Some studies using pluripotent stem cells reported the possibility of this approach. Otsuji et al. reported that human ES cell-derived cardiomyocytes in 3D culture demonstrated an increased level of acH3 and increased expression of cardiac-specific genes, such as alpha myosin heavy chain (MYH6), ERG1b, and KCNQ1, compared with those in adhesion culture [46] . They also reported that trichostatin A (TSA), a selective inhibitor of the class I and ІI mammalian HDAC families [47, 48] , significantly upregulated the acH3 level of human ES cell-derived cardiomyocytes compared with that of dimethyl sulfoxide (DMSO)-treated controls. TSA also increased the expression of ERG1b and KCNQ1 in human ES cell-derived cardiomyocytes, as determined by quantitative RT-PCR. Global gene expression analysis showed that human ES cell-derived cardiomyocytes treated with TSA exhibited significant upregulation of two of eight sodium ion channel-related genes, two of sixteen calcium ion channel-related genes, and sixteen of forty-nine potassium ion channel-related genes in human ES cell-derived cardiomyocytes. TSA also increased the electrophysiological function of human ES cell-derived cardiomyocytes in a multi-electrode array. Chow et al. showed that valproic acid (VPA), an HDAC inhibitor like TSA [49] , augmented the levels of H3K4me3 on the promoter of MYH6, NPPA, Ca 2+ -handling protein, and sodium and potassium ion channels, and the expression of these genes in human ES cell-derived ventricular cardiomyocytes, although VPA did not improve the electrophysiological properties of the cells in Ca transient analysis [43] . Ohtani et al. created mouse ES cells with the knockout of jumonji domain-containing protein 3 (Jmjd3), which is also known as H3K27 demethylase [50, 51] , and differentiated these cells into cardiomyocytes [52] . They showed the reduced expression of Brachyury, a mesoderm marker of the T-box genes [53] , and Mixl1, a mesoderm marker classified into the Mix/Bix family of paired-like homeobox genes [54] , in the Jmjd3 -/-embryoid bodies (EBs) during differentiation, compared with those in wild-type EBs. The reduced expression of Brachyury and Mixl1 in Jmjd3 -/-EBs was caused by the enrichment of H3K27me3 marks due to the knockout of Jmjd3. They also demonstrated the significant suppression of genes for cardiac development, such as Mesp1, Pdgfa, Nppa, Mef2c, Tnnt2, and Myh6, and lower contractility in Jmjd3 -/-EBs compared with those of wild-type EBs. Horrillo et al. reported that zebularine, a cytidine analogue that inhibits DNA methyltransferases [55] and which is more stable and less toxic than 5'-aza-2'-deoxycytidine (AzadC) [56, 57] , induced demethylation of Nkx2.5 promoter in mouse ES cells during cardiac differentiation, which in turn induced the upregulation of cardiac-specific genes, such as Nppa, Flk1, Hrt1, Mef2c, Actc, Tnnt2, Myh7, Myl2, and Myl7, in zebularine-treated EBs compared with those in untreated EBs. Zebularine also increased the number of more contractile EBs that responded well to the cardiotropic agents [58] . These reports suggest the possibility of treating impaired cardiac development using chemical reagents that modify epigenetic regulation.
A barrier to epigenetic study using iPS cells: epigenetic memory
By using stem cell technologies, we can recapitulate the cardiogenesis during differentiation in vitro, which enables us to investigate cardiogenesis more safely and intensively. When it comes to pluripotent stem cells, we have two main types: ES cells and iPS cells. These pluripotent stem cells are known to have almost the same properties: they express similar gene expression patterns, proliferate unlimitedly, and differentiate into any designed type of cell. However, iPS cells have a special feature: epigenetic memory. Epigenetic memory is the phenomenon by which iPS cells still have the epigenetic signature of the donor somatic cells, even after reprogramming [59, 60] . This epigenetic memory is caused by incomplete silencing of the donor cell-specific gene expression patterns; the majority of this is attributed to DNA methylation [61, 62] because histone modifications were shown to be similar between iPS cells and ES cells [63, 64] . Numerous studies have reported that epigenetic memory is seen in the early passage phases of iPS cells and could cause variable differentiation potential; that is, iPS cells are more likely to differentiate into their original cell types [61, 65, 66] . Some reports have shown that epigenetic memory remained in iPS cells even after passages, but others demonstrated that repeated passages could eliminate the epigenetic differences among iPS cells derived from their original different types of somatic cells. Kim et al. compared the epigenetic modification during differentiation between umbilical cord blood-derived iPS cells and neonatal keratinocyte-derived iPS cells [66] . They concluded that the umbilical cord blood-derived iPS cells more potently differentiated into hematopoietic cells than keratinocyte-derived iPS cells, and the keratinocyte-derived iPS cells had better potential to differentiate into keratinocytes than the umbilical cord blood-derived iPS cells, from the results of DNA methylation patterns and microarray analyses. They also commented that the epigenetic memory did not disappear after passages. Polo et al. generated mouse iPS cells derived from tail tip-derived fibroblasts, splenic B cells, bone marrow-derived granulocytes, and skeletal muscle precursors and compared them [67] . The iPS cells from the different cell types demonstrated distinct epigenetic modifications and differential potentials, which were specific to their original cell types. In contrast to the findings of Kim et al., Polo et al. reported that the repeated passage of iPS cells eliminated their transcriptional, epigenetic, and functional differences among those with different original cell types. In addition, Sanchez-Freire et al. generated iPS cells from CPCs and skin fibroblasts from the same donors and differentiated them into cardiomyocytes [68] . They showed that there were significantly higher rates of TNNT2-positive cells and beating EBs in the CPC-iPS-derived cardiomyocytes than in the fibroblast-iPS-derived ones. The CPC-derived iPS cells also demonstrated significantly upregulated expression of cardiac-specific genes such as NKX2-5, MESP1, ISL1, HAND2, MYOCD, MEF2C, and GATA4 during cardiomyocyte differentiation compared with the fibroblast-derived ones. They also showed that the fibroblast-iPS-derived cardiomyocytes had significantly higher DNA methylation at the NKX2-5 promoter than the CPC-iPS-derived ones. These findings indicate that the CPCs-derived iPS cells had more cardiomyogenic potential than the fibroblast-derived ones. [69] . As a result, they reported that the epigenetic memory in iPS cells accounted for the small rate of variability between iPS cells and ES cells. Rouhani et al. generated 9 fibroblast-derived iPS cells, 6 keratinocyte-derived iPS cells, and 10 endothelial progenitor cell-derived iPS cells from 4 adult donors and analyzed the iPS cells, the donor cells, and 2 human ES cell lines by RNA sequencing [70] . They concluded that epigenetic memory from the donor cells is rare in human iPS cells, and the variation between iPS lines is more likely to occur due to the changing genetic backgrounds.
Conclusions
Some cases of congenital heart diseases are caused by the mutation of definite cardiac-specific genes or related chromosomal abnormalities [1] , but the causes of most cases are unknown. The impaired expression of multiple genes seemed to be involved in the pathogenesis of congenital heart diseases and the lack of animal models has hampered studies. Recently, we identified a new approach to dissect the complicated pathogenesis: epigenetic regulation. Recent studies have accumulated knowledge on the epigenetic regulation during cardiac development, and impaired epigenetic regulation has been shown to cause congenital heart defects [2, 3] . To study epigenetic regulation, stem cell technologies could be a powerful tool. We can recapitulate the cardiogenesis during the differentiation from stem cells into cardiomyocytes without changing DNA sequences, and we can investigate and also modify the epigenetic regulation of cardiac development in vitro during these processes. Several studies using stem cell technologies have revealed the relationship between stage-specific epigenetic regulation and stage-specific cardiac gene expression [37, 38] , and also succeeded in improving the altered epigenetic regulation and gene expression during cardiac development in vitro by using chemical reagents that modify chromatins [43, 46, 52, 58] . These results suggest that we could treat some congenital heart diseases by using chemical reagents. However, for iPS cells, we have to take the issue of epigenetic memory into consideration, namely, the retention of the epigenetic signature of somatic cells from which iPS cells originated [59, 60] . Numerous studies have reported that iPS cells retained epigenetic memory and that they tended to differentiate into their original cell types [61, 65, 66] . Epigenetic memory has thus complicated study of the differentiation of iPS cells. In terms of this phenomenon, variable findings have been reported: some studies claimed that epigenetic memory accounted for only a small proportion of the variability [69, 70] and disappeared after repeated passages [67, 68] , while others reported that epigenetic memory remained [66] . Indeed, there are certain difficulties associated with the use of iPS cells, but they have fascinating features compared with ES cells, so they could be used as disease models. In contrast to ES cells, which are created from embryos, iPS cells are generated from somatic cells. Thus, we can generate iPS cells from patients with specific diseases in order to model and recapitulate the disease phenotypes during differentiation. This might enable us to dissect the complicated pathogenesis in vitro. With regard to the use of iPS cells, some suggestions can now be proposed. When we differentiate iPS cells into a designed type of cell, it would be better to select iPS cells generated from that particular type of somatic cell. Some studies have proved the significant differences in differentiation potential among designed cells to differentiate into other types of cell [66] [67] [68] . In our experiments, we generated iPS cells from CPCs and differentiated them into cardiomyocytes [44] . This strategy might be reasonable, especially for research using patient-specific iPS cells, which are often resistant to differentiation. Of course, the obtainment of somatic cells designed to differentiate into certain cell types, like neurons, would be difficult. In such cases, we should use iPS cells for differentiation study after repeated passages. By overcoming and utilizing epigenetic memory, iPS cells could become a more promising cell source for stem cell research. Knowledge of epigenetic regulation would enable us to understand cardiac development and the pathogenesis of congenital heart diseases in more detail, and for the investigation of epigenetic modification, stem cell technologies would be necessary.
